Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ARCT 
Arcturus Therapeutics Holdings Inc (ARCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ARCT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $67.4
1 Year Target Price $67.4
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.12% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 360.97M USD | Price to earnings Ratio - | 1Y Target Price 67.4 |
Price to earnings Ratio - | 1Y Target Price 67.4 | ||
Volume (30-day avg) 11 | Beta 2.29 | 52 Weeks Range 8.04 - 25.88 | Updated Date 06/30/2025 |
52 Weeks Range 8.04 - 25.88 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-06-13 | When After Market | Estimate -1.19 | Actual -0.52 |
Profitability
Profit Margin -47.47% | Operating Margin (TTM) -57.27% |
Management Effectiveness
Return on Assets (TTM) -13.67% | Return on Equity (TTM) -27.4% |
Valuation
Trailing PE - | Forward PE 2.48 | Enterprise Value 186956431 | Price to Sales(TTM) 2.51 |
Enterprise Value 186956431 | Price to Sales(TTM) 2.51 | ||
Enterprise Value to Revenue 1.42 | Enterprise Value to EBITDA -25.67 | Shares Outstanding 27120600 | Shares Floating 24984584 |
Shares Outstanding 27120600 | Shares Floating 24984584 | ||
Percent Insiders 7.89 | Percent Institutions 93 |
Analyst Ratings
Rating 4 | Target Price 67.4 | Buy 3 | Strong Buy 8 |
Buy 3 | Strong Buy 8 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Arcturus Therapeutics Holdings Inc
Company Overview
History and Background
Arcturus Therapeutics Holdings Inc. was founded in 2013. It is a clinical-stage messenger RNA (mRNA) medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Key milestones include developing its LUNAR lipid delivery platform and advancing several mRNA therapeutic and vaccine candidates through clinical trials.
Core Business Areas
- mRNA Medicines: Developing mRNA therapeutics targeting a range of diseases, including rare genetic disorders and infectious diseases.
- Vaccines: Creating mRNA-based vaccines for infectious diseases, including COVID-19.
- LUNAR Delivery Platform: Developing and licensing its proprietary LUNAR lipid-mediated delivery platform for nucleic acids.
Leadership and Structure
The leadership team includes Joseph Payne (President and CEO). The organizational structure is typical of a biotech company, with research, development, clinical, and commercial departments.
Top Products and Market Share
Key Offerings
- ARCT-154 (COVID-19 vaccine): A next-generation mRNA COVID-19 vaccine candidate. Market share is still developing, facing competition from Pfizer/BioNTech (PFE), Moderna (MRNA), and Novavax (NVAX). It is approved in Indonesia and has a small market share there.
- ARCT-810 (Ornithine Transcarbamylase (OTC) Deficiency): An mRNA therapeutic candidate for the treatment of OTC deficiency. Currently in clinical development, so no market share yet. Competitors are limited as it is a rare disease but include companies developing gene therapies like Ultragenyx (RARE).
- LUNAR Delivery Platform: Proprietary lipid delivery system for mRNA and siRNA therapeutics. It's not a direct product but enables other products. Its impact on market share is indirect.
Market Dynamics
Industry Overview
The mRNA therapeutics and vaccines market is rapidly growing, driven by the success of mRNA COVID-19 vaccines. Key trends include increased investment in mRNA technology, expansion into new therapeutic areas, and advancements in delivery technologies.
Positioning
Arcturus is a mid-sized player in the mRNA space, focusing on developing novel therapies and vaccines using its LUNAR delivery platform. Its competitive advantages include its proprietary technology and focus on rare diseases.
Total Addressable Market (TAM)
The global mRNA therapeutics and vaccines market is projected to reach hundreds of billions of dollars in the next decade. Arcturus is positioned to capture a share of this TAM through its pipeline of mRNA therapeutics and vaccines.
Upturn SWOT Analysis
Strengths
- Proprietary LUNAR delivery platform
- Strong intellectual property portfolio
- Experienced management team
- Focus on rare diseases with unmet needs
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on clinical trial success
- Relatively small commercial infrastructure
- Dependence on partnerships for certain programs
Opportunities
- Expanding mRNA technology into new therapeutic areas
- Securing regulatory approvals for its vaccine candidates
- Forming strategic partnerships with larger pharmaceutical companies
- Developing personalized mRNA therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- NVAX
- LLY
Competitive Landscape
Arcturus faces intense competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. Its advantage lies in its LUNAR delivery platform and focus on specific therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancements in its mRNA platform and clinical programs, though fluctuating based on trial results and partnerships.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its pipeline products. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include advancing its COVID-19 vaccine candidate ARCT-154 through clinical trials and expanding its pipeline of mRNA therapeutics for rare diseases.
Summary
Arcturus Therapeutics is a clinical-stage mRNA company with a promising LUNAR delivery platform. Its success depends on clinical trial outcomes and commercialization efforts, especially for ARCT-154. Competition is fierce, particularly from larger companies like Moderna and BioNTech. They need to secure partnerships to help with funding and manufacturing. While its focus on rare diseases presents opportunities, potential setbacks include regulatory hurdles and clinical trial failures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Arcturus Therapeutics Holdings Inc. website
- SEC Filings
- Company Press Releases
- Analyst Reports
- Market research reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcturus Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-04-16 | Founder, President, CEO & Director Mr. Joseph E. Payne M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 174 | Website https://arcturusrx.com |
Full time employees 174 | Website https://arcturusrx.com | ||
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.